Platelet Rich Plasma vs Hyaluronic-Acid in Hip OA (Osteoarthritis)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01920152|
Recruitment Status : Enrolling by invitation
First Posted : August 9, 2013
Last Update Posted : April 17, 2019
|Condition or disease||Intervention/treatment||Phase|
|Hip Osteoarthritis||Biological: PRP Device: Hyaluronic Acid||Not Applicable|
Osteoarthritis (OA) is a common, painful condition affect adults and causes mobility disability in the United States and Europe. Unfortunately, there is no agents available that halt OA progression. Analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) have suboptimal effectiveness, and there is concern of systemic side effects.
A large challenge is the development of appropriate and effective therapy in patients with OA. Currently, the most suitable route for administering OA therapy appears to be intra-articular injections that allow accumulation of critical doses of the drug within the damaged area and also reduce the risk of systemic side effects.
The primary objective of this study is to compare the clinical efficacy of intra-articular injections of Platelet Rich Plasma (PRP) vs. Hyaluronic Acid for symptomatic early OA of the hip. Secondarily, the study aims to evaluate the safety and feasibility of both medications delivered.
Patients, which meet inclusion criteria, are confirmed eligible, and agree to enroll in the study, would be randomized and treated with either three intra-articular PRP injections or three intra-articular Hyaluronic Acid injections. If the patient has OA in both hips, they will be randomized to receive the same injection in both hips. The Primary investigator will be unblinded to the treatment that the subject is randomized to. The PI will only be involved in the initial assessment of the patient and the actual injections. All of the follow up visits, clinical assessments and outcome scores will be performed by the sub-investigator, who will also be the examining physician. The sub-investigator will be blinded to the treatment throughout the study. All of the study subjects will be blinded to which treatment that they are assigned to.
Physical exams will be performed to assess range of motion of the hip joint. The difference in ranges of motion will be statistically compared at different time points between the two groups to determine the difference in improvement between the two compared to baseline.
The primary efficacy outcome will be defined as the percentage of patients having a 50% decrease in the summed score for the WOMAC pain subscale from baseline to week 24. We will measure this outcome by applying the WOMAC questionnaire compared with baseline therapy. The secondary efficacy outcomes will also include IHOT and Non Arthritic Hip Score.
An anterior posterior hip radiograph will be performed at 12 months and 24 months to assess Kellgren-Classification and compared to baseline.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||A Randomized Clinical Trial Evaluating Platelet Rich Plasma Versus Hyaluronic-Acid in the Short-term Treatment of Symptomatic OA (Osteoarthritis) of the Hip|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
Experimental: Autologous PRP Hip Injection
Patients (n=40) randomized to this group of treatment will receive 3 blinded hip intra-articular injections of autologous Platelet-Rich Plasma one week apart from each other.
Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
Active Comparator: Hyaluronic Acid Hip Injection
Patients (n=40) randomized to this group of treatment will receive 3 blinded hip intra-articular injections of hyaluronic acid (SUPARTZ hyaluronate/2.5ml) one week apart each other.
Device: Hyaluronic Acid
Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
Other Name: SUPARTZ
- Change in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) [ Time Frame: Baseline-24 months follow up ]The primary efficacy outcome will be defined as the percentage of patients having a 50% decrease in the summed score for the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale from baseline to week 24.
- Change in International Hip Outcome Tool (IHOT) [ Time Frame: Baseline-24 months post inoculation ]Subjective score variation in the International Hip Outcome Tool (IHOT) for both groups of treatment from baseline to 24 months post inoculation
- Change in Non Arthritic Hip Score [ Time Frame: Baseline-24 months ]Subjective score variation on the Non Arthritic Hip Score for both groups of treatment from baseline to 24 months post inoculation
- Change in Hip Range of motion (ROM) [ Time Frame: Baseline-24 months ]Score variation on hip range of motion for both groups of treatment from baseline to 24 months post inoculation
- Change in FABER TEST [ Time Frame: Baseline-24 months ]Score variation for FABER test for both groups of treatment from baseline to 24 months post inoculation
- Change in Anterior Posterior (AP) Pelvis Radiograph/ Kellgren-Lawrence classification. [ Time Frame: Baseline-24 months ]Score variation on the Kellgren-Lawrence score for both groups of treatment from baseline to 24 months post inoculation
- Number of patients with Adverse Events [ Time Frame: Week 2-Week 3 and 6-12-18-24 months ]Type, duration and trend of every adverse event for each patient will be reported
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01920152
|United States, Colorado|
|University of Colorado, Hip Preservation Center, Orthopedic Department|
|Boulder, Colorado, United States, 80304|
|Principal Investigator:||Omer Mei-Dan, MD||University of Colorado, Denver|